Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCT07185815 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Bipolar I Disorder
Major Depressive Disorder

Interventions

DRUG: Cariprazine Depot
DRUG: Cariprazine Depot
DRUG: Cariprazine Depot MTD
DRUG: Oral Cariprazine 3 mg/day

Sponsor

Mapi Pharma Ltd.